Thymalfasin and Radiotherapy Explored for Abscopal Effect in Metastatic Lung Cancer

Small Cell Lung Cancer (SCLC) is an aggressive malignancy often presenting with metastatic lesions, making treatment challenging and prognosis poor. While radiotherapy can effectively target local tumors, a rare but powerful phenomenon known as the abscopal effect occurs when local radiation triggers a systemic anti-tumor immune response, impacting distant untreated lesions. This Phase II study aimed to investigate if combining thymalfasin (an immune modulator) with radiotherapy could enhance this abscopal effect in patients with heavily pretreated, metastatic SCLC.

This Phase II study (NCT ID: NCT02542137) was unfortunately WITHDRAWN before any patients could be enrolled or treated, meaning no experimental data was collected or reported. > The most significant finding is that this investigation into the abscopal effect of Thymalfasin and radiotherapy in metastatic Small Cell Lung Cancer did not yield any results due to its withdrawal. Consequently, there are no specific quantitative findings regarding immunity-mediated tumor responses, the effectiveness of the combination therapy, or the utility of PET/CT scanning for this purpose. The study, initially planned to run from September 2015 to December 2019, concluded without providing insights into its stated objectives.